AR100820A1 - Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas - Google Patents

Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas

Info

Publication number
AR100820A1
AR100820A1 ARP150101871A ARP150101871A AR100820A1 AR 100820 A1 AR100820 A1 AR 100820A1 AR P150101871 A ARP150101871 A AR P150101871A AR P150101871 A ARP150101871 A AR P150101871A AR 100820 A1 AR100820 A1 AR 100820A1
Authority
AR
Argentina
Prior art keywords
formulations
layer
capecitabine
cyclofosphamide
fractioned
Prior art date
Application number
ARP150101871A
Other languages
English (en)
Original Assignee
Sanofi-Synthelabo (India) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo (India) Ltd filed Critical Sanofi-Synthelabo (India) Ltd
Publication of AR100820A1 publication Critical patent/AR100820A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación de comprimido oral bi-capa de ciclofosfamida y capecitabina y métodos de preparación de estas formulaciones. Además, dichas formulaciones son útiles para administración metronómica para tratar cáncer, por ejemplo, cáncer de mama. Reivindicación 4: La formulación de comprimido de una cualquiera de las reivindicaciones 1 a 3, en la que el único comprimido bi-capa está recubierto con película. Reivindicación 7: La formulación de comprimido de la reivindicación 6, en la que el recubrimiento con película aplicado comprende la composición siguiente: @@@@@@@@@
ARP150101871A 2014-06-12 2015-06-11 Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas AR100820A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1596DE2014 2014-06-12

Publications (1)

Publication Number Publication Date
AR100820A1 true AR100820A1 (es) 2016-11-02

Family

ID=53724388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101871A AR100820A1 (es) 2014-06-12 2015-06-11 Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas

Country Status (3)

Country Link
AR (1) AR100820A1 (es)
TW (1) TW201613563A (es)
WO (1) WO2015189807A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809658UA (en) * 2016-05-03 2018-11-29 Intas Pharmaceuticals Ltd Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143212A1 (en) * 2006-06-02 2007-12-13 Ariad Gene Therapeutics, Inc. Capecitabine combination therapy
US20140309183A1 (en) * 2011-08-24 2014-10-16 David Kerr Low-Dose Combination Chemotherapy
BR112016007031A8 (pt) * 2013-09-30 2020-02-27 Intas Pharmaceuticals Ltd composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida

Also Published As

Publication number Publication date
TW201613563A (en) 2016-04-16
WO2015189807A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CO2018008207A2 (es) Composiciones para el cuidado bucal y métodos para utilizar las composiciones
MY196173A (en) Cot Modulators And Methods Of Use Thereof
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
ECSP17053843A (es) Formulación nasal en polvo para el tratamiento de hipoglicemia
CL2020001226A1 (es) Proceso para preparar tapinarof.
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
PH12016502386A1 (en) Oral care compositions
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
AR100820A1 (es) Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite

Legal Events

Date Code Title Description
FB Suspension of granting procedure